Search

Smith & Nephew PLC

Fermé

1,230.5 -0.81

Résumé

Variation du prix de l'action

24h

Actuel

Min

1228

Max

1249

Chiffres clés

By Trading Economics

Revenu

296M

Ventes

3B

P/E

Moyenne du Secteur

30.037

23.145

BPA

0.429

Rendement du dividende

3.09

Marge bénéficiaire

9.895

Employés

17,000

EBITDA

723M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+18.71% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.09%

4.30%

Prochains Résultats

2 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.5B

10B

Ouverture précédente

1231.31

Clôture précédente

1230.5

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 janv. 2026, 23:07 UTC

Résultats

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 janv. 2026, 21:27 UTC

Résultats

Texas Instruments 4Q Sales Rise, Profit Falls

27 janv. 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 janv. 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 janv. 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 janv. 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 janv. 2026, 23:20 UTC

Résultats

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 janv. 2026, 23:20 UTC

Résultats

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 janv. 2026, 23:19 UTC

Résultats

SK Innovation Posts Net Loss for Second Consecutive Year

27 janv. 2026, 23:19 UTC

Résultats

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 janv. 2026, 23:18 UTC

Résultats

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 janv. 2026, 23:18 UTC

Résultats

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 janv. 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27 janv. 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 janv. 2026, 23:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 janv. 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 janv. 2026, 22:06 UTC

Résultats

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 janv. 2026, 21:51 UTC

Résultats

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 janv. 2026, 21:43 UTC

Résultats

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 janv. 2026, 21:41 UTC

Résultats

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 janv. 2026, 21:38 UTC

Résultats

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 janv. 2026, 21:32 UTC

Résultats

Ampol: Modest Profit From F&I International in 2025

27 janv. 2026, 21:32 UTC

Résultats

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 janv. 2026, 21:31 UTC

Résultats

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 janv. 2026, 21:31 UTC

Résultats

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 janv. 2026, 21:30 UTC

Résultats

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 janv. 2026, 21:29 UTC

Résultats

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 janv. 2026, 21:29 UTC

Résultats

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 janv. 2026, 21:28 UTC

Résultats

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

18.71% hausse

Prévisions sur 12 Mois

Moyen 1,465.5 GBX  18.71%

Haut 1,650 GBX

Bas 1,290 GBX

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

5

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat